MCID: HYP263
MIFTS: 40

Hypersomnia

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia 53 17 70

Classifications:



External Ids:

UMLS 70 C0917799

Summaries for Hypersomnia

NINDS : 53 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, snoring and sleep disturbances. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Translocation of ZAP-70 to Immunological synapse and MHC class II antigen presentation. The drugs Sodium oxybate and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include eye, hypothalamus and cortex.

Wikipedia : 73 Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 idiopathic hypersomnia 32.1 HLA-DRB1 HLA-DQB1 HCRT
2 recurrent hypersomnia 32.1 HLA-DQB1 HCRT
3 kleine-levin hibernation syndrome 32.0 HLA-DQB1 HCRT
4 neuromyelitis optica 30.2 HLA-DRB1 HCRT
5 narcolepsy 29.8 HLA-DRB1 HLA-DQB1 HCRT CPT1B CHKB
6 acute disseminated encephalomyelitis 29.7 HLA-DRB1 HLA-DQB1 HCRT
7 optic neuritis 29.6 HLA-DRB1 HLA-DQB1
8 narcolepsy 2 29.2 HLA-DRB1 HLA-DQB1 HCRT
9 guillain-barre syndrome 29.2 HLA-DRB1 HLA-DQB1 HCRT
10 sleep disorder 11.1
11 major depressive disorder 11.0
12 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.0
13 myotonic dystrophy 2 10.9
14 atypical depressive disorder 10.9
15 sleep apnea 10.5
16 major affective disorder 8 10.3
17 major affective disorder 9 10.3
18 bipolar disorder 10.3
19 mood disorder 10.3
20 mental depression 10.2
21 depression 10.2
22 myotonic dystrophy 10.1
23 encephalopathy 10.1
24 encephalitis 10.1
25 limbic encephalitis with lgi1 antibodies 10.1 HLA-DRB1 HLA-DQB1
26 autoimmune polyglandular syndrome type 3 10.1 HLA-DRB1 HLA-DQB1
27 htlv-1 associated myelopathy/tropical spastic paraparesis 10.1 HLA-DRB1 HLA-DQB1
28 latent autoimmune diabetes in adults 10.1 HLA-DRB1 HLA-DQB1
29 occupational asthma 10.1 HLA-DRB1 HLA-DQB1
30 primary adrenal insufficiency 10.1 HLA-DRB1 HLA-DQB1
31 recurrent respiratory papillomatosis 10.1 HLA-DRB1 HLA-DQB1
32 beryllium disease 10.1 HLA-DRB1 HLA-DQB1
33 apple allergy 10.1 HLA-DRB1 HLA-DQB1
34 chronic beryllium disease 10.1 HLA-DRB1 HLA-DQB1
35 metal allergy 10.1 HLA-DRB1 HLA-DQB1
36 autoimmune hepatitis 10.1 HLA-DRB1 HLA-DQB1
37 autoimmune hepatitis type 1 10.1 HLA-DRB1 HLA-DQB1
38 focal epithelial hyperplasia 10.1 HLA-DRB1 HLA-DQB1
39 pediatric multiple sclerosis 10.1 HLA-DRB1 HLA-DQB1
40 podoconiosis 10.1 HLA-DRB1 HLA-DQB1
41 pemphigoid 10.1 HLA-DRB1 HLA-DQB1
42 osteonecrosis of the jaw 10.1 HLA-DRB1 HLA-DQB1
43 pityriasis rosea 10.1 HLA-DRB1 HLA-DQB1
44 dysthymic disorder 10.1
45 brain injury 10.1
46 traumatic brain injury 10.1
47 oligoarticular juvenile idiopathic arthritis 10.1 HLA-DRB1 HLA-DQB1
48 idiopathic nephrotic syndrome 10.1 HLA-DRB1 HLA-DQB1
49 ocular cicatricial pemphigoid 10.1 HLA-DRB1 HLA-DQB1
50 cicatricial pemphigoid 10.1 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


excessive daytime somnolence; snoring; sleep disturbances; sleeplessness; insomnia with sleep apnea, unspecified; hypersomnia with sleep apnea, unspecified; disruption of 24 hour sleep wake cycle, unspecified; [d]sleep disturbances (& [hypersomnia] or [insomnia])

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
2
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
3
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 5881
4
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
5 DHEA (Dehydroepiandrosterone) Phase 2, Phase 3
6 Immunologic Factors Phase 2, Phase 3
7 Adjuvants, Immunologic Phase 2, Phase 3
8 Pharmaceutical Solutions Phase 2, Phase 3
9 Anesthetics Phase 2, Phase 3
10 Anesthetics, General Phase 2, Phase 3
11 Anesthetics, Intravenous Phase 2, Phase 3
12 Citrate Phase 2, Phase 3
13
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
14
Clarithromycin Approved Phase 2 81103-11-9 84029
15
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
16
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
17
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
18
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
19 Antidotes Phase 1, Phase 2
20 Protective Agents Phase 1, Phase 2
21 GABA Modulators Phase 1, Phase 2
22 Cytochrome P-450 CYP3A Inhibitors Phase 2
23 Cytochrome P-450 Enzyme Inhibitors Phase 2
24 Anti-Bacterial Agents Phase 2
25 Anti-Infective Agents Phase 2
26 Dopamine Agents Phase 2
27 Sympathomimetics Phase 2
28 adderall Phase 2
29 Dopamine Uptake Inhibitors Phase 2
30 Adrenergic Agents Phase 2
31 Antibiotics, Antitubercular Phase 2
32 Neurotransmitter Agents Phase 2
33 Central Nervous System Stimulants Phase 2
34 Convulsants Phase 2
35 Pentylenetetrazole Phase 2 54-95-5
36
Caffeine Approved 58-08-2 2519

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
2 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Completed NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
3 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
4 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
5 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
6 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
7 Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines Recruiting NCT03772314 Phase 2 Modafinil;Amphetamine-Dextroamphetamine
8 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
9 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Active, not recruiting NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
10 Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1 Completed NCT03959189 Phase 1 ERX-963;Placebo
11 A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia Completed NCT04091438 Phase 1 TAK-925;TAK-925 Placebo
12 Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases Completed NCT01877616
13 Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia. Completed NCT01926405
14 Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial Completed NCT03904238
15 Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia Completed NCT03459300
16 Brief Sleep Intervention for Suicide in Bipolar Disorder Completed NCT01764074
17 Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders Completed NCT00001664
18 Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia Completed NCT02913651
19 Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation Completed NCT01719315
20 Mind-Body Approach to Improve Health-Related Quality of Life for People With Narcolepsy Recruiting NCT04306952
21 Assessing the Effect of the MYODM Food Supplement on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Recruiting NCT04634682
22 Hypersomnia in Major Depressive Disorder Recruiting NCT04006834
23 Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy Terminated NCT03198156
24 Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Withdrawn NCT03626727 Early Phase 1 Sodium Oxybate Oral Solution [Xyrem]

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

40
Eye, Hypothalamus, Cortex, Thalamus, Pituitary, Brain, Ovary

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 1896)
# Title Authors PMID Year
1
Sleep phenotype of individuals with autism spectrum disorder bearing mutations in the PER2 circadian rhythm gene. 61
33474825 2021
2
Treatment of severe morning sleep inertia with bedtime long-acting bupropion and/or long-acting methylphenidate in a series of 4 patients. 61
33179592 2021
3
Efficacy and safety of modafinil in patients with idiopathic hypersomnia without long sleep time: a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison study. 61
33631500 2021
4
Actigraphy measurement of physical activity and energy expenditure in narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia: A Sensewear Armband study. 61
32281246 2021
5
Idiopathic hypersomnia: a homogeneous or heterogeneous disease? 61
33588261 2021
6
Evaluation of pathological sleepiness by Multiple Sleep Latency Test and 24-hour polysomnography in patients suspected of idiopathic hypersomnia. 61
33448529 2021
7
Traumatic Brain Injury and Incidence Risk of Sleep Disorders in Nearly 200,000 US Veterans. 61
33658328 2021
8
Automatic analysis of single-channel sleep EEG in a large spectrum of sleep disorders. 61
33089777 2021
9
The association between sleep disturbances and negative symptom severity in patients with non-affective psychotic disorders, unaffected siblings and healthy controls. 61
33493731 2021
10
Sleep disorders in children with asthma. 61
33647191 2021
11
Kleine-Levin syndrome is associated with birth difficulties and genetic variants in the TRANK1 gene loci. 61
33737391 2021
12
Microsleep assessment enhances interpretation of the Maintenance of Wakefulness Test. 61
33729911 2021
13
Multiple Sleep Latency Test: when are 4 naps enough? 61
33146124 2021
14
Microsleep assessment enhances interpretation of the Maintenance of Wakefulness Test. 61
33715771 2021
15
Factor analysis of depression symptoms across five broad cultural groups. 61
33418371 2021
16
Is REM sleep a paradoxical state?: Different neurons are activated in the cingulate cortices and the claustrum during wakefulness and paradoxical sleep hypersomnia. 61
33713640 2021
17
False-positive cases in multiple sleep latency test by accumulated sleep debt. 61
33749139 2021
18
[Physical exercise impact on variables related to emotional and functional well-being in older adults]. 61
33775433 2021
19
Regional brain metabolism differentiates narcolepsy type 1 and idiopathic hypersomnia. 61
33693888 2021
20
Effects of transcranial direct current stimulation on performance and recovery sleep during acute sleep deprivation: a pilot study. 61
33524838 2021
21
Multiple sleep latency test and polysomnography in patients with central disorders of hypersomnolence. 61
33453460 2021
22
A strange New Year's Eve: triggers in Kleine-Levin syndrome. 61
33025902 2021
23
Clinical manifestations and polysomnography-based analysis in nine cases of probable sporadic Creutzfeldt-Jakob disease. 61
33559029 2021
24
Autonomic dysfunction in childhood hypersomnia disorders. 61
33385777 2021
25
Hypogonadism in Patients with Prader Willi Syndrome: A Narrative Review. 61
33671467 2021
26
Impact of Cognitive Measures and Sleep on Acute Squat Strength Performance and Perceptual Responses Among Well-Trained Men and Women. 61
31373979 2021
27
Associations between insomnia and reward learning in clinical depression. 61
33634765 2021
28
Can network analysis of self-reported psychopathology shed light on the core phenomenology of bipolar disorders in adolescents and young adults? 61
33638252 2021
29
3 Tesla serial magnetic resonance imaging of human African trypanosomiasis (Trypanosoma brucei gambiense) and review of the literature. 61
33648780 2021
30
[Differential diagnosis of hypersomnia in surgical sleep medicine-more than just sleep apnea!] 61
32885308 2021
31
Dissecting the Association Between Inflammation, Metabolic Dysregulation, and Specific Depressive Symptoms: A Genetic Correlation and 2-Sample Mendelian Randomization Study. 61
33079133 2021
32
Structures of active-state orexin receptor 2 rationalize peptide and small-molecule agonist recognition and receptor activation. 61
33547286 2021
33
Neurodevelopmental Disorders Commonly Presenting with Sleep Disturbances. 61
33403472 2021
34
When Night Falls Fast: Sleep and Suicidal Behavior Among Adolescents and Young Adults. 61
33223066 2021
35
Accuracy of Actigraphy Compared to Concomitant Ambulatory Polysomnography in Narcolepsy and Other Sleep Disorders. 61
33746882 2021
36
Clinical features of paediatric and adult autoimmune encephalitis: A multicenter sample. 61
33461084 2021
37
Sleep disturbances and first onset of major mental disorders in adolescence and early adulthood: A systematic review and meta-analysis. 61
33549912 2021
38
An update on epidemiology, diagnosis & management of NMO-SD in the tertiary neurology department of Marrakech (Morocco). 61
32741562 2021
39
The (mis)perception of sleep: factors influencing the discrepancy between self-reported and objective sleep parameters. 61
33393901 2021
40
Maintenance of wakefulness test: how does it predict accident risk in patients with sleep disorders? 61
32778442 2021
41
Insights into the Frequency and Distinguishing Features of Sleep Disorders in Pediatric Palliative Care Incorporating a Systematic Sleep Protocol. 61
33477321 2021
42
Height, weight, and cardiovascular effects of stimulants on children with brain tumors. 61
33049111 2021
43
Excessive sleepiness in patients with psychosis: An initial investigation. 61
33449971 2021
44
Activating autoantibodies against G protein-coupled receptors in narcolepsy type 1. 61
33341642 2021
45
Impact of COVID-19 pandemic lockdown on narcolepsy type 1 management. 61
33247632 2021
46
Compromised Dynamic Cerebral Autoregulation in Patients With Central Disorders of Hypersomnolence. 61
33776891 2021
47
On-the-road driving performance of patients with central disorders of hypersomnolence. 61
33543997 2021
48
Cerebrospinal fluid monoamine levels in central hypersomnolence disorders. 61
33476396 2021
49
Stability of Nocturnal Wake and Sleep Stages Defines CNS Disorders of Hypersomnolence. 61
33512510 2021
50
The importance of specialized sleep investigations in children with a suprasellar tumor. 61
32691357 2020

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.4 HLA-DRB1 HLA-DQB1
2 endocytic vesicle membrane GO:0030666 9.37 HLA-DRB1 HLA-DQB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.32 HLA-DRB1 HLA-DQB1
4 transport vesicle membrane GO:0030658 9.26 HLA-DRB1 HLA-DQB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DRB1 HLA-DQB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DRB1 HLA-DQB1
7 MHC class II protein complex GO:0042613 8.62 HLA-DRB1 HLA-DQB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.37 HLA-DRB1 HLA-DQB1
2 interferon-gamma-mediated signaling pathway GO:0060333 9.32 HLA-DRB1 HLA-DQB1
3 antigen processing and presentation GO:0019882 9.26 HLA-DRB1 HLA-DQB1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.16 HLA-DRB1 HLA-DQB1
5 humoral immune response mediated by circulating immunoglobulin GO:0002455 8.96 HLA-DRB1 HLA-DQB1
6 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.62 HLA-DRB1 HLA-DQB1

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DRB1 HLA-DQB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DRB1 HLA-DQB1

Sources for Hypersomnia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....